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Abstract
 
Using three different Fc
 
g
 
 receptor (Fc
 
g
 
R)-deficient mouse strains, we examined the induction
of autoimmune hemolytic anemia by each of the four immunoglobulin (Ig)G isotype-switch
variants of a 4C8 IgM antierythrocyte autoantibody and its relation to the contributions of the
two Fc
 
g
 
R, Fc
 
g
 
RI, and Fc
 
g
 
RIII, operative in the phagocytosis of opsonized particles. We
found that the four IgG isotypes of this antibody displayed striking differences in pathogenicity,
which were related to their respective capacity to interact in vivo with the two phagocytic
Fc
 
g
 
Rs, defined as follows: IgG2a 
 
. 
 
IgG2b 
 
. 
 
IgG3/IgG1 for Fc
 
g
 
RI, and IgG2a 
 
. 
 
IgG1 
 
.
 
IgG2b 
 
. 
 
IgG3 for Fc
 
g
 
RIII. Accordingly, the IgG2a autoantibody exhibited the highest patho-
 
genicity, 
 
z
 
20–100-fold more potent than its IgG1 and IgG2b variants, respectively, while the
IgG3 variant, which displays little interaction with these Fc
 
g
 
Rs, was not pathogenic at all. An
unexpected critical role of the low-affinity Fc
 
g
 
RIII was revealed by the use of two different
IgG2a anti–red blood cell autoantibodies, which displayed a striking preferential utilization of
Fc
 
g
 
RIII, compared with the high-affinity Fc
 
g
 
RI. This demonstration of the respective roles in
vivo of four different IgG isotypes, and of two phagocytic Fc
 
g
 
Rs, in autoimmune hemolytic
anemia highlights the major importance of the regulation of IgG isotype responses in autoanti-
body-mediated pathology and humoral immunity.
Key words: autoantibody • autoimmune hemolytic anemia • Fc receptor • IgG isotype • 
knockout mouse
 
Introduction
 
NZB mice spontaneously develop an autoimmune hemo-
lytic anemia as a result of production of Coombs’ anti-
RBC autoantibodies (1). Although the specificity of anti-
RBC autoantibodies is of primary importance in the ex-
pression of their pathogenic activities in vivo, effector
functions associated with the Fc regions of the different Ig
isotypes are also likely to play a critical role. Among the
various effector functions mediated by the Ig heavy-chain
constant regions, it is striking to see that the complement
activation plays a minimal, if any, role in the development
of anemia induced by anti-RBC antibodies (2, 3). In con-
 
Address correspondence to Dr. Shozo Izui, Department of Pathology,
Centre Médical Universitaire, 1 rue Michel-Servet, Geneva 4, 1211,
Switzerland. Phone: 41-22-70-25-741; Fax: 41-22-70-25-746; E-mail:
shozo.izui@medecine.unige.ch 
1294
 
IgG Isotype Dependence of Autoimmune Hemolytic Anemia
 
trast, IgG Fc receptor (Fc
 
g
 
R)
 
1
 
-mediated erythrophagocy-
tosis has been recognized as the major pathogenic mecha-
nism responsible for autoimmune hemolytic anemia in
mice (2, 4–7).
Murine phagocytic effector cells express three different
classes of Fc
 
g
 
R: a high-affinity receptor, Fc
 
g
 
RI, and two
low-affinity receptors, Fc
 
g
 
RII and Fc
 
g
 
RIII (for reviews,
see references 8–10). Fc
 
g
 
RI and Fc
 
g
 
RIII are heterooligo-
meric complexes, in which the respective ligand-binding 
 
a
 
chains are associated with the common 
 
g
 
 chain (FcR
 
g
 
).
FcR
 
g
 
 is required for their assembly and for the triggering
of their various effector functions, including phagocytosis
by macrophages, degranulation by mast cells, and antibody-
dependent cell-mediated cytotoxicity by NK cells (11). In
contrast, Fc
 
g
 
RII is a single 
 
a
 
 chain receptor, with two ma-
jor isoforms, Fc
 
g
 
RIIb1 and Fc
 
g
 
RIIb2 (12), both of which
apparently lack phagocytosis-inducing capacity (11). The
macrophage-specific isoform, Fc
 
g
 
RIIb2, is capable of me-
diating the binding and endocytosis of IgG immune com-
plexes (ICs), thereby facilitating antigen processing and
presentation, whereas the b1 isoform, mainly expressed in
B lymphocytes, is not efficiently internalized upon binding
of IgG ICs, but mediates inhibition of surface IgM–trig-
gered B cell activation after coligation (13–15). The high-
affinity receptor, Fc
 
g
 
RI, is capable of binding monomeric
IgG2a (16–18), and the two low-affinity receptors, Fc
 
g
 
RII
and Fc
 
g
 
RIII, bind polymeric IgG of different IgG isotypes
except IgG3 (19). Thus, it has been proposed that IgG2a
ICs interact preferentially with the high-affinity Fc
 
g
 
RI,
IgG1, and IgG2b ICs with the low-affinity Fc
 
g
 
R. In addi-
tion, a more recent in vitro study has claimed that IgG3 ICs
selectively interact with Fc
 
g
 
RI (20). By the use of Fc
 
g
 
R-
deficient mice, it has now been well established that Fc-
 
g
 
RIII is the sole receptor mediating IgG1-dependent
phagocytosis in vivo (6, 7, 21). However, the precise con-
tribution of each of these two Fc
 
g
 
R to phagocytize op-
sonized particles with IgG2a, IgG2b, or IgG3 antibodies
remains to be defined.
In view of the major role of Fc
 
g
 
R-mediated erythro-
phagocytosis in the pathogenesis of autoimmune hemolytic
anemia (4–7), the in vivo pathogenicity of anti-RBC au-
toantibodies of different IgG isotypes may be critically de-
pendent on the relative affinities of two different phago-
cytic Fc
 
g
 
Rs (Fc
 
g
 
RI and Fc
 
g
 
RIII) to the polymeric form
of each IgG isotype. This question cannot be explored
through the use of a random panel of monoclonal anti–
mouse-RBC autoantibodies differing in Ig isotypes, as they
may also differ in antigen-binding specificities and affinities.
We have recently prepared an IgG2a class-switch variant
from the NZB-derived 4C8 anti-RBC IgM monoclonal
autoantibody (2), and found it highly pathogenic as the re-
sult of its efficient interaction with phagocytic Fc
 
g
 
R (22).
Therefore, we have generated three other IgG class-switch
variants (IgG1, IgG2b, and IgG3) of this mAb, and com-
 
pared their pathogenic potency with that of the IgG2a vari-
ant in relation to their utilization of the two classes of
phagocytic Fc
 
g
 
R, as explored by the use of three different
strains of Fc
 
g
 
R-deficient mice. We observed remarkable
differences in the pathogenic potentials of these IgG variant
autoantibodies. These differences appear to be determined
by the capacity of individual IgG isotypes to interact in
vivo with the low-affinity Fc
 
g
 
RIII. Thus, the results have
defined the respective roles of the two different phagocytic
Fc
 
g
 
Rs in vivo, providing a rational for the IgG isotype–
dependent pathogenicity observed in autoimmune hemolytic
anemia.
 
Materials and Methods
 
Mice.
 
Fc
 
g
 
RIII-deficient (Fc
 
g
 
RIII
 
2/2
 
) mice lacking the 
 
a
 
chain of Fc
 
g
 
RIII with a mixed genetic background between
C57BL/6 and 129 strains, FcR
 
g
 
-deficient (FcR
 
g
 
2/2
 
) mice (lack-
ing functional expression of both Fc
 
g
 
RI and Fc
 
g
 
RIII) with a
pure C57BL/6 background, and their corresponding wild-type
(WT) littermates were developed as described previously (21,
23). Fc
 
g
 
RI-deficient (Fc
 
g
 
RI
 
2/2
 
) mice lacking the 
 
a
 
 chain of Fc-
 
g
 
RI were generated in the laboratory of J. S. Verbeek (Leiden
University) by homologous recombination, backcrossed for four
generations with BALB/c mice, and bred to homozygosity at the
 
fcgrI
 
 null allele (our unpublished results). BALB/c mice were pur-
chased from Gl. Bomholtgard Ltd.
 
DNA Constructions.
 
The VDJH4C8-C
 
g
 
1, -C
 
g
 
2b, and -C
 
g
 
3
plasmids containing the complete 4C8 IgG heavy-chain gene of
the respective IgG subclass were constructed using the following
DNA fragments: the rearranged VDJ region isolated from cDNA
encoding the V region of the heavy chain of the 4C8 mAb (24),
the promoter region isolated from pSV-V
 
m
 
1 (25), the heavy
chain enhancer region isolated from pSVE2-neo (26), and the
C
 
g
 
1, C
 
g
 
2b, or C
 
g
 
3 region derived from the respective genomic
clones, pEVHC
 
g
 
1 (26), pIgH22 (27), and pJW7 (28).
 
mAb.
 
The 4C8 IgG1, IgG2b, and IgG3 class-switch variants
were obtained by transfecting 4C8 heavy-chain-loss mutant cells
by electroporation with the VDJH4C8-C
 
g
 
 plasmids together
with a pSVE2-neo plasmid containing the neomycin-resistant
gene, as described for the generation of the 4C8 IgG2a variant
(22). Clones secreting 
 
z
 
2–5 
 
m
 
g/ml were selected and used in
this study. The 4C8 IgG class-switch variants exhibited a compa-
rable mouse RBC-binding activity in vitro, as assessed by a flow
cytometric analysis using a biotinylated rat anti–mouse 
 
k
 
-chain
mAb (H139.52.1.5), followed by PE-conjugated streptavidin
(22). Notably, the VH4C8 and V
 
k
 
4C8 sequences of the 4C8
heavy- and light-chain cDNA derived from a reverse tran-
scriptase PCR amplification of mRNA isolated from the cells se-
creting 4C8 IgG switch variants were identical to the original
published sequence (24). Hybridoma secreting 34-3C IgG2a
anti–mouse RBC mAb was derived from nonmanipulated NZB
mice (2). S54 IgG1 anti-4C8 idiotypic mAb recognizing the
combination of both the heavy and light chains of the 4C8 mAb
was obtained as described (29). Other mAbs in use were: IgG2a
anti-TNP (Hy1.2), IgG1 anti-SRBC (Sp3HL), IgG2b anti-
SRBC (N-S.8.1), rat IgG2b anti-CD4 (GK1.5), and rat IgG2b
anti-CD8 (H35-17.2) mAbs. IgG mAbs were purified from cul-
ture supernatants by protein A or protein G column chromatog-
raphy. The purity of IgG was 
 
.
 
90% as documented by SDS-
PAGE.
 
1
 
Abbreviations used in this paper: FcgR, Fc receptor; FcRg, FcR common
g chain; Ht, hematocrit; IC, immune complex; WT, wild-type.1295 Fossati-Jimack et al.
Reverse Transcriptase PCR and cDNA Sequencing. RNA was pre-
pared from 4C8 IgG transfectomas by RNeasy Mini Kit (Qiagen
AG). The first strand of cDNA was synthesized with an oligo(dT)
primer and 5 mg of total RNA. For amplification with Pfu DNA
polymerase (Stratagene Cloning Systems), the following primers
were used: 59-untranslated VH primer (59-CAGTTCTCTCTACA-
GTTA-39), Cg2b-CH1 primer (59-GCCAGTGGATAGAC-39),
Cg1/3-CH1 primer (59-GGATAGACAGATGG-39) for the 4C8
heavy-chain, and 59-untranslated Vk primer (59-CAGGGGAA-
GCAAGATGG-39) and Ck primer (59-TGGATGGTGGGAA-
GATG-39) for the 4C8 light chain. The nucleotide sequence cor-
responding to the V region of the 4C8 heavy or light chain was
determined by the dideoxynucleotide chain terminating method
(30).
ELISA. Concentrations of mAbs in culture supernatants
were quantified by IgG subclass-specific ELISA, as described pre-
viously (31). The expression of the 4C8 idiotype in sera was de-
termined by ELISA. In brief, globulins from serum samples were
first separated by precipitation in ammonium sulfate at 50% satu-
ration, and the precipitate resuspended in 0.05 M carbonate
buffer (pH 9.5) at a dilution of 1:1,000 was used for coating mi-
crotiter plates. Then, the assay was developed with alkaline phos-
phatase–labeled S54 anti-4C8 idiotypic mAb.
Experimental Autoimmune Hemolytic Anemia. Autoimmune
hemolytic anemia was induced by a single intraperitoneal injec-
tion of purified anti-RBC mAb into 2–3-mo-old mice. In some
experiments, 107 transfectoma or hybridoma cells were injected
intraperitoneally into pristane-treated mice. As the transfectoma
cells were derived from a fusion of NZB spleen cells with a
BALB/c myeloma cell line, expressing the H-2d haplotype, pris-
tane-treated mice were given a mixture of anti-CD4 (GK1.5) and
anti-CD8 (H35-17.2) mAbs (500 mg of each mAb) 1 d previously
and 1 d after the transplantation of the transfectoma cells to avoid
their rejection, as described previously (32). Blood samples were
collected into heparinized microhematocrit tubes, and hemat-
ocrits (Ht) were directly determined after centrifugation, as de-
scribed previously (2).
Histological Studies. Livers were obtained at autopsy, pro-
cessed for histological examination, and stained with hematox-
ylin and eosin. The extent of in vivo RBC destruction by
Kupffer cell–mediated phagocytosis was determined by Perls iron
staining.
In Vitro Phagocytosis of IgG-opsonized SRBCs by Macrophages.
Peritoneal macrophages were obtained from mice pretreated with
thioglycollate, and adhered for 4 h at 378C on chamber slides
(Nunc) at a concentration of 3 3 105 cells per well. Then, ali-
quots of 200 ml of 5% SRBC opsonized with Sp3HL IgG1 or
N-S.8.1 IgG2b anti-SRBC mAb at nonagglutinating titers were
added to each well, and the plates were incubated for 60 min at
378C. Extracellular SRBCs were lysed by hypotonic shock, im-
mediately followed by two washes with PBS. The percentage of
positive macrophages (i.e., those containing more than two SR-
BCs) was determined by light microscopy.
Statistical Analysis. Statistical analysis was performed with the
Wilcoxon two-sample test. Probability values .5% were consid-
ered insignificant.
Results
Marked Differences in Pathogenic Activities among the 4C8
IgG Isotype-Switch Variants. The role of the IgG heavy-
chain C region of anti–mouse RBC autoantibodies on the
development of anemia was first analyzed by a single intra-
peritoneal injection of 1 mg of the four different IgG class-
switch variants of the 4C8 mAb into BALB/c mice. The
IgG2a variant induced the most severe form of anemia (a
decrease in mean Ht values to 21% at day 4), the IgG1 vari-
ant a mild anemia (average Ht of 36%), and the IgG2b and
IgG3 variants were unable to significantly decrease Ht levels
(Fig. 1 A). Quantitative analysis revealed that 50 mg of the
4C8 IgG2a mAb was sufficient to induce anemia (mean Ht
values of three mice 4 d after the injection: 36 6 3%) at a
level comparable to that observed with 1 mg of the 4C8
IgG1 isotype. For the 4C8 IgG2b variant, a dose as high as
5 mg caused a significant, though marginal, drop in Ht val-
ues (means of four mice: 46 6 1% at day 0; 41 6 2% at day
4; P , 0.01), whereas up to 5 mg of the 4C8 IgG3 variant
had no detectable effects (means of four mice: 47 6 2% at
day 0; 45 6 2% at day 4), as was the case of mice injected
with a control IgG2a anti-TNP mAb (data not shown).
Thus, the pathogenic potency of the 4C8 IgG2a isotype
was z20-fold, 100-fold, and still much higher than that of
the IgG1, IgG2b, and IgG3 isotypes, respectively.
To compare more precisely the potency of the two less
pathogenic isotypes, IgG2b- and IgG3-secreting transfecto-
mas were implanted intraperitoneally into BALB/c mice.
The 4C8 IgG2b transfectoma cells provoked severe anemia,
with a decrease in mean Ht values to 31 and 18% at day 6
and 8, respectively, whereas Ht values remained within
normal limits (.40%) in mice transplanted with 4C8 IgG3
or Hy1.2 IgG2a anti-TNP hybridoma cells (Fig. 1 B). The
secretion of excess amounts of the 4C8 IgG3 mAb in vivo
was documented by the presence of substantial amounts of
free antibodies bearing the 4C8 idiotype (data not shown).
With the three anemia-inducing isotypes, histological ex-
aminations showed that the most remarkable pathological
change was erythrophagocytosis by hepatic Kupffer cells.
The extent of erythrophagocytosis, documented by iron
deposits in Kupffer cells, correlated with the level of anemia
induced by these three different IgG switch variants (Fig. 2).
Figure 1. Development of anemia by the 4C8 IgG class-switch variants
in BALB/c mice. (A) Mice were injected intraperitoneally with 1 mg of
purified 4C8 IgG variants (IgG1, s; IgG2a, d; IgG2b, h; IgG3, m) on
day 0. Results are expressed as mean Ht values of three to five mice. (B)
Mice were transplanted intraperitoneally with 107 cells secreting 4C8
IgG2b (h), 4C8 IgG3 (m), or Hy1.2 IgG2a anti-TNP (s) on day 0. Re-
sults are expressed as mean Ht values of five to seven mice.1296 IgG Isotype Dependence of Autoimmune Hemolytic Anemia
It should be mentioned that although Ht values in mice re-
ceiving 5 mg 4C8 IgG2b remained within normal limits,
significant iron deposits in Kupffer cells were observed; this
was markedly augmented in mice implanted with the 4C8
IgG2b transfectoma. In contrast, Kupffer cell–mediated
erythrophagocytosis and iron deposits were totally absent in
the 4C8 IgG3-injected mice, even following the transplan-
tation of 4C8 IgG3 cells (Fig. 2). Moreover, these mice
failed to show a massive accumulation of agglutinated
RBCs in spleen and liver, unlike mice injected with the
4C8 IgM mAb (2).
Differential Contributions of FcgRI and FcgRIII to the Devel-
opment of Anemia in Relation to the 4C8 IgG Isotypes. By
using three different mouse strains—strains deficient in Fc-
gRI, FcgRIII, or FcRg (i.e., lacking functional expression
of both FcgRI and FcgRIII)—we next investigated the re-
spective contribution of two different classes of phagocytic
FcgR and FcgRIII to the anemia induced by IgG1, IgG2a,
and IgG2b isotype variants of the 4C8 mAb.
The development of anemia occurring in WT mice in-
Figure 2. Representative histological ap-
pearance of iron deposits in Kupffer cells
from FcgR-deficient and WT mice after the
injection of the 4C8 IgG class-switch vari-
ants. Mice were injected intraperitoneally
with either purified antibodies or 107 4C8
IgG-secreting cells, and killed at day 8. Ex-
tent of in vivo RBC destruction by phago-
cytosis was revealed by coloration of liver
sections with Perls iron staining. Note com-
plete absence of iron deposits in livers from
FcgRIII2/2 mice injected with the 4C8
IgG1 mAb, from FcRg2/2 mice receiving
4C8 IgG2a or IgG2b variant, and from WT
mice transplanted with the 4C8 IgG3 trans-
fectoma (original magnifications: 3200).
Table I.  Development of Anemia in FcgR-deficient and WT 
Mice after the Injection of the 4C8 IgG1 and IgG2a Variants
Isotype Dose Mice Ht*
%
IgG1 1 mg WT (4)‡ 36.3 6 2.9
FcgRIII2/2 (5) 46.6 6 0.9
IgG2a 200 mg WT (4) 31.0 6 2.0
FcgRIII2/2 (4) 45.7 6 2.1
1 mg WT (7) 21.5 6 3.7
FcgRIII2/2 (7) 37.2 6 2.3
FcgRI2/2 (5) 27.6 6 3.9
FcRg2/2 (4) 44.6 6 1.8
*Ht values (mean 6 1SD) were determined 4 d after the intraperitoneal
injection of purified 4C8 IgG variants. Ht values before the injection of anti-
RBC mAB in WT and FcgR-deficient mice were in the 44–48% range.
‡Numbers of mice studied are indicated in parentheses.1297 Fossati-Jimack et al.
jected with 1 mg 4C8 IgG1 mAb was completely prevented
in FcgRIII2/2 mice (Table I), which failed to exhibit eryth-
rophagocytosis, as documented by the lack of iron deposits
in their Kupffer cells (Fig. 2). The far more severe eryth-
rophagocytosis observed in WT mice after the transplanta-
tion of the 4C8 IgG1 transfectoma was also abolished in
FcgRIII2/2 mice (Fig. 2), indicating that FcgRIII is the sole
receptor involved in the 4C8 IgG1-mediated erythro-
phagocytosis by Kupffer cells.
Although FcgRIII2/2 mice were also totally resistant to
the pathogenic effect of 200 mg 4C8 IgG2a variant, a less se-
vere, but significant anemia with a lower extent of eryth-
rophagocytosis was still induced in these mice by a higher
dose (1 mg) of the 4C8 IgG2a (P , 0.001) (Table I, and Fig.
2). This indicated that FcgRIII plays a major role in the 4C8
IgG2a-induced anemia, but that FcgRI is also involved in
Figure 3. Development of anemia in FcgR-deficient and WT mice af-
ter the transplantation of the 4C8 IgG2b transfectoma. 107 transfectoma
cells were injected into (A) FcgRIII2/2 (s) or WT littermates (d); (B)
FcgRI2/2 (e) or WT littermates (d); and (C) FcRg2/2 (n) or WT lit-
termates (d) on day 0. Ht values of individual mice measured every 2 d
are shown.
Figure 4. Development of
anemia in FcgRIII2/2 and WT
mice after the injection of the
34-3C IgG2a mAb. 200 or 50
mg of the mAb was injected in-
traperitoneally into FcgRIII2/2
(s) or WT littermates (d) on
day 0. Ht values of individual
mice measured 4 d after the mAb
injection are shown. Note the
complete prevention of anemia
in FcgRIII2/2 mice injected
with 50 mg of the 34-3C mAb.
the severe anemia caused by higher amounts of this isotype.
This conclusion was confirmed by the use of two other
strains of FcgR-deficient mice, in which the level of protec-
tion from the pathogenic effect of 1 mg 4C8 IgG2a mAb
was found to be more limited in FcgRI-deficient mice than
in FcgRIII-deficient mice (P , 0.005), but complete in
FcRg2/2 mice lacking both receptors (Table I and Fig. 2).
In contrast to the IgG1 and IgG2a variants, the develop-
ment of a severe anemia provoked by the transplantation of
the 4C8 IgG2b transfectoma was almost indistinguishable
in kinetics and histological changes among FcgRIII2/2,
FcgRI2/2, and WT mice (Fig. 2 and Fig. 3). However,
FcRg2/2 mice deficient in both FcgRI and FcgRIII were
resistant to the pathogenic effect of the 4C8 IgG2b, as eryth-
rophagocytosis by Kupffer cells was no longer visible in these
mice (Fig. 2 and Fig. 3). Notably, serum levels of antibodies
bearing the 4C8 idiotype, measured at killing (6–8 d after the
transplantation of the 4C8 IgG2b cells), were comparable
between FcgR-deficient mice and their corresponding WT
mice (data not shown). It should also be stressed that both
FcgRI2/2 and FcgRIII2/2 mice injected with 5 mg of the
4C8 IgG2b exhibited a modest hepatic erythrophagocytosis
at levels comparable to that of WT mice (data not shown).
These results indicated that the involvement of both FcgRI
and FcgRIII in hemolytic anemia is induced by very high
doses of the 4C8 IgG2b variant.
Major Contribution of FcgRIII to the Development of Anemia
by 34-3C IgG2a Anti–Mouse RBC mAb. Previous studies
have demonstrated the contribution of both FcgRI and
FcgRIII to the development of anemia after the injection
of a highly pathogenic dose of the 34-3C IgG2a anti–
mouse RBC mAb (5, 7). As the present studies revealed a
critical role of FcgRIII in the development of anemia in-
duced by a lower dose of the 4C8 IgG2a variant, we reas-
sessed the pathogenic effect of the 34-3C IgG2a mAb in
FcgRIII2/2 mice compared with WT mice. The develop-
ment of anemia was partially prevented in FcgRIII2/2 mice
after the injection of a highly pathogenic dose (200 mg) of
the 34-3C mAb, which caused a severe anemia in WT
mice (P , 0.05). However, it was completely prevented
after the injection of a lower dose (50 mg) that still caused
anemia in WT mice (P , 0.005; Fig. 4). These results con-
firmed the prominent role of FcgRIII over FcgRI in the
IgG2a anti-RBC–induced autoimmune hemolytic anemia.
Contribution of Both FcgRI and FcgRIII to Phagocytosis of
IgG2b-opsonized SRBCs by Peritoneal Macrophages In Vitro.
An intriguing observation made in this study was the sig-1298 IgG Isotype Dependence of Autoimmune Hemolytic Anemia
nificant contribution of FcgRI to the development of
IgG2b-induced erythrophagocytosis, as it has been thought
that murine IgG2b ICs are unable to interact with the
high-affinity FcgRI (33). As no other IgG2b anti–mouse
RBC mAb capable of inducing erythrophagocytosis in
vivo was available, we analyzed the in vitro phagocytosis of
SRBCs opsonized with murine IgG2b anti-SRBC mAb by
thioglycollate-elicited peritoneal macrophages derived
from mice deficient in FcgRI and/or FcgRIII. Phagocyto-
sis of IgG2b-opsonized SRBCs by macrophages lacking ei-
ther FcgRI or FcgRIII was not affected at all, whereas
FcRg-deficient macrophages failed to display significant
phagocytosis of these opsonized SRBCs (Fig. 5 A). Mac-
rophages from FcgRI2/2 mice exhibited phagocytosis of
IgG1-opsonized SRBCs as strong as those from WT mice,
whereas this phagocytic activity was hardly detectable by
macrophages lacking FcgRIII (Fig. 5 B).
Discussion
We have generated four IgG class-switch variants bear-
ing identical VH and Vk regions, those of a pathogenic
4C8 IgM anti–mouse RBC autoantibody derived from lu-
pus-prone NZB mice, and determined their potency in the
induction of autoimmune hemolytic anemia in relation to
the respective contributions of two different classes of
phagocytic FcgR, namely, the high-affinity FcgRI and the
low-affinity FcgRIII. The IgG2a isotype interacting most
efficiently with both FcgRI and FcgRIII exhibited the
highest hemolytic activity, followed by the IgG1 isotype
having a substantial affinity to FcgRIII, and then by the
IgG2b isotype capable of interacting only weakly with both
receptors. The IgG3 isotype lacking significant binding to
these FcgRs displayed no pathogenicity at all. Further-
more, our results have demonstrated preferential utilization
of FcgRIII by the IgG2a isotype in vivo, despite their low-
affinity interaction compared with FcgRI, revealing the
major role of the low-affinity FcgRIII in autoimmune
hemolytic anemia.
Differential Contributions of FcgRI and FcgRIII to IgG Iso-
type-dependent Anti-RBC Pathogenicity. It was striking to
observe how different the utilization by individual IgG iso-
types of the two different types of FcgR involved in eryth-
rophagocytosis in vivo is, as reflected in the pathogenesis of
autoimmune hemolytic anemia (Table II). The complete
absence of erythrophagocytosis by the 4C8 IgG1 variant in
FcgRIII2/2 mice confirmed the critical role of FcgRIII in
the IgG1-mediated erythrophagocytosis, as shown recently
by using another 105-2H IgG1 anti–mouse RBC mono-
clonal autoantibody (6, 7). Significantly, our study dis-
closed that the contribution of FcgRIII to the develop-
ment of IgG2a-induced autoimmune hemolytic anemia is
more prominent than that of FcgRI. This was somehow
unexpected, as the high-affinity binding of FcgRI to the
IgG2a isotype has been well established (16–18, 33). How-
ever, it should be stressed that FcgRI contributes to IgG2a-
dependent erythrophagocytosis, but only when higher
doses of IgG2a anti–mouse RBC mAb were injected. A
limited utilization of FcgRI for phagocytosis of IgG2a-
opsonized RBCs may be due to the competition by excess
amounts of unbound circulating monomeric IgG2a having
a high-affinity interaction with FcgRI. In this regard, it
may be worth noting that a significant anemia was still ob-
served in FcgRIII2/2 mice injected with 200 mg of the 34-
3C IgG2a, but not with the same amount of the 4C8
IgG2a. Thus, it appears that the contribution of the high-
affinity FcgRI to pathogenicity is more influenced by the
antigen-binding properties of the IgG2a antibodies. In
agreement with this conclusion, we have recently shown
that in vivo bindings to circulating RBCs were much
stronger with the 34-3C mAb than with the 4C8 IgG2a,
reflecting marked differences in RBC-binding affinities of
these two antibodies (22). Thus, it is likely that higher den-
sities of the 34-3C IgG2a bound on RBCs may efficiently
compete with circulating monomeric IgG2a for FcgRI
binding on phagocytes. An alternative, or additional possi-
bility is that the IgG2a anti-RBC mAb at higher doses
could mediate erythrophagocytosis by their direct binding
to FcgRI, followed by subsequent interaction of cell-
bound antibodies with circulating RBCs. Owing to its
higher RBC-binding capacity, the FcgRI-bound 34-3C
mAb on the surface of phagocytes may be much more effi-
cient to capture circulating RBCs, causing erythrophago-
cytosis, compared with the low-affinity 4C8 IgG2a.
An additional and unexpected observation was that of a
significant role of FcgRI in the pathogenesis of 4C8
Figure 5. In vitro phagocytosis of IgG2b- and IgG1-opsonized SRBCs
by macrophages from FcgR-deficient and WT mice. Adherent thiogly-
collate-elicited peritoneal macrophages from WT, FcgRIII2/2, FcgRI2/2,
and FcRg2/2 mice were incubated with SRBCs opsonized with N-S.8.1
IgG2b (A) or Sp3HL IgG1 (B) anti-SRBC mAb. Phagocytosis was deter-
mined after lysing extracellular SRBCs by a hypotonic shock. Results are
expressed as the percentage (means 6 SEM of triplicate cultures) of posi-
tive macrophages that had ingested more than two SRBCs.1299 Fossati-Jimack et al.
IgG2b-induced autoimmune hemolytic anemia. Indeed, it
has long been believed that the IgG2b isotype is unable to
interact with the high-affinity FcgRI (33). However, it
should be emphasized that the latter conclusion was based
on the results obtained with COS cells expressing FcgRI a
chains in absence of the FcR g chain (33, 34). The Fc re-
ceptors expressed on those transfected cells exhibit binding
to monomeric IgG2a and IgG2a-coated RBCs. However,
these receptors do not appear to behave as do heterooligo-
meric complexes of the native receptor normally borne on
phagocytic effector cells, as FcgRI is functionally absent in
FcRg-deficient peritoneal macrophages and Kupffer cells
(5, 11). It has also been noted that the affinity of the FcgRI
expressed on the transfected COS cells is two- to fivefold
lower than that of the native receptor, but is restored at
normal levels through their association with FcRg (18, 35,
36). This could account for the lack of detectable binding
of IgG2b-opsonized RBCs to COS cells transfected with
murine FcgRIa cDNA (33), because of a weak affinity of
FcgRI to IgG2b ICs, as discussed below. On the other
hand, our demonstration that 4C8 IgG2b-dependent
erythrophagocytosis by Kupffer cells was little affected by
the absence of FcgRIII is in good agreement with in vitro
studies using peritoneal macrophages isolated from mice
deficient in FcgRIII (6, 21). However, it should be em-
phasized that Kupffer cell–mediated erythrophagocytosis in
WT mice injected with 5 mg of purified antibodies or
transplanted with the 4C8 IgG2b-secreting cells was not af-
fected in FcgRI2/2 mice, but completely protected in
FcRg2/2 mice lacking both FcgRI and FcgRIII. The pres-
ence of very high concentrations of the 4C8 IgG2b mAb in
these experimental conditions may promote the utilization
of FcgRI, as discussed above for the IgG2a isotype. Con-
sequently, FcgRI and FcgRIII are able to efficiently
compensate each other to mediate the phagocytosis of
IgG2b-opsonized RBCs in vivo. As we could not assess the
respective role of both receptors at lower concentrations of
the IgG2b isotype, in contrast with the situation with the
4C8 IgG2a isotype, our present conclusion, that the com-
parable contribution of FcgRI and FcgRIII to the IgG2b-
induced anemia, is still tentative (Table II). Only experi-
ments with a highly pathogenic IgG2b anti-RBC mAb
would provide definitive conclusions on this issue.
The complete dependency of IgG-mediated erythro-
phagocytosis on FcgRI and/or FcgRIII confirms a lack of
phagocytosis-inducing capacity by FcgRII, though capable
of mediating endocytosis of polymeric IgG (13, 14). On
the other hand, it has been demonstrated that FcgRII-defi-
cient mice exhibited higher humoral, anaphylactic, and in-
flammatory immune responses that underline the impor-
tance of FcgRII for the negative regulation of B cell
receptor–, FceRI-, and FcgRIII-dependent effector func-
tions in vivo (15, 37, 38). However, we have recently
shown that FcgRII is unable to downregulate FcgRIII-
mediated phagocytosis of RBCs opsonized with 105-2H
IgG1 anti-RBC mAb in vivo (39). Although the possible
negative effect of FcgRII on FcgRI-dependent erythro-
phagocytosis cannot be excluded, our preliminary analysis
with the 34-3C IgG2a mAb in FcgRII-deficient mice ar-
gues against such a possibility.
Relative Affinities of FcgRI and FcgRIII to the Polymeric
Forms of the Four Different Murine IgG Isotypes. Our re-
sults help clarify the issue regarding the relative affinity of
each of these two FcgRs to the different IgG isotypes in
vivo, and hence, the respective roles of the four different
IgG isotypes in the pathogenesis of autoimmune hemolytic
anemia. With respect to the affinity of FcgRI to polymeric
form of murine IgG isotypes, our study reveals that FcgRI
has a significant affinity to IgG2b ICs, as discussed above.
However, its affinity to IgG2b ICs is much lower than that
to IgG2a ICs, as FcgRI-mediated erythrophagocytosis was
observed in FcgRIII2/2 mice with 1 and 5 mg of the 4C8
IgG2a and IgG2b variants, respectively. Recently, using
bone marrow–derived macrophages from FcgRI-deficient
mice, FcgRI has been reported to be the sole receptor for
the IgG3 isotype (20). However, we did not observe any
significant erythrophagocytosis by Kupffer cells in WT
mice, even after the implantation of 4C8 IgG3 cells. In
agreement with this observation, a recent study has re-
ported that an IgG3 mAb against cryptococcal capsular
Table II.  Pathogenetic Activities of the 4C8 IgG Class-Switch Variants, Respective Contributions of FcgRI and FcgRIII to the Development 
of Anemia Induced by the 4C8 IgG Variants, and Their Relative Affinities to ICs of the Four IgG Isotypes
Affinity of
Isotype Pathogenicity*
Contribution of FcgR to 4C8 
IgG-induced anemia FcgRI‡ FcgRIII‡
IgG1 11 (1 mg) FcgRIII 21 1
IgG2a 111 (50 mg) FcgRIII . FcgRI 11 111
IgG2b 1 (.5 mg) FcgRI/FcgRIII 11
IgG3 2 None 22
*Minimum amounts of mAb required for inducing anemia (decreasing Ht values ,40%) are indicated in parentheses.
‡The relative affinity of FcgRI and FcgRIII to ICs of the four different IgG isotypes is arbitrarily graded on the base of in vivo evidence of eryth-
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polysaccharide failed to provoke phagocytosis through Fc-
gRI and FcgRIII in vitro and in vivo (40). Together with
the complete protection from the pathogenic effect of the
4C8 IgG1 variant in FcgRIII2/2 mice, we propose that the
relative in vivo binding activity of FcgRI to antigen–anti-
body complexes of different murine IgG isotypes is in the
order of IgG2a . IgG2b . IgG3/IgG1 (Table II).
Based on in vitro studies using macrophages or trans-
fected cell lines (17, 19), it has been proposed that FcgRIII
has a comparable affinity to IgG1, IgG2b, and IgG2a, but
little affinity to IgG3. Although we confirmed that FcgRIII
is capable of mediating phagocytosis of RBCs opsonized
with IgG1, IgG2b, and IgG2a, but not with IgG3, our anal-
ysis has clearly demonstrated marked differences in the rela-
tive affinity of FcgRIII to these three IgG isotypes; highest
for IgG2a, intermediate for IgG1, and lowest for IgG2b
(Table II). This conclusion is based on the finding that Fc-
gRIII-dependent erythrophagocytosis was inducible at a
dose of 50 mg, 1 mg, and 5 mg of the 4C8 IgG2a, IgG1,
and IgG2b isotypes, respectively. However, it should be
mentioned that IgG2b ICs are potent to induce passive cu-
taneous anaphylaxis upon triggering FcgRIII expressed on
mast cells (6). An efficient activation of mast cells by IgG2b
ICs may be related to the fact that unlike macrophages, mast
cells express a unique form of FcgRIII associated with the
FcR b chain, which functions as an amplifier of FcgRIII
responses by enhancing FcRg-mediated signaling (41).
Does Complement Play Any Role in Autoimmune Hemolytic
Anemia? The present results are consistent with the previ-
ous conclusion that complement-mediated hemolysis and
complement receptor–dependent erythrophagocytosis may
play but a minor, if any, role in this model of autoimmune
hemolytic anemia. The development of 34-3C IgG2a-
induced anemia was indeed not affected at all in C5-deficient
DBA/2 mice or in C3-depleted mice by the treatment with
cobra venom factor (2, 7). This is further supported by the
recent demonstration that mice genetically deficient in C3
were not protected from anemia caused by polyclonal rab-
bit IgG anti–mouse RBC antibodies, whereas loss of both
FcgRI and FcgRIII prevented the anemia (3). However,
these results cannot completely exclude the possible role of
C4 in autoimmune hemolytic anemia, as the C4b fragment
is recognized by the complement receptor type I (CR1),
which stimulates phagocytosis (for a review, see reference
42). In addition, in vivo clearance experiments of RBCs
sensitized with polyclonal rabbit IgG anti-RBC antibodies
in C4-deficient guinea pigs have shown that erythrophago-
cytosis can be mediated by the synergistic cooperation of
FcgR and complement receptors expressed on Kupffer cells
(43). Such a mechanism could be operative under certain
conditions, depending on the extent of opsonization and
the IgG isotypes of anti-RBC autoantibodies. If so, the dif-
ferential ability of individual IgG isotypes to activate the
complement pathway may additionally contribute to the re-
markable differences in the pathogenicity observed in this
report. Clearly, more detailed analysis on C3- and C4-defi-
cient mice in relation to the IgG isotypes of anti-RBC au-
toantibodies, their RBC-binding affinities, and the extent
of RBC opsonization could help to define a role for com-
plement in the development of autoimmune hemolytic
anemia.
Concluding Remarks. The use of the four different anti-
RBC IgG switch variants bearing identical VH and Vk
regions has provided a unique opportunity to define the re-
spective roles of two different phagocytic FcgRs in IgG iso-
type–dependent effector functions, and hence, the patho-
genic potency of individual murine IgG isotypes. Strikingly,
the capacity of each IgG isotype to interact with the low-
affinity FcgRIII is the critical factor determining the patho-
genic potency of individual IgG isotypes, as the high-
affinity FcgRI apparently plays a relatively limited role,
probably because of the competition by circulating mono-
meric IgG2a. In addition, our results should provide useful
guiding principles for the engineering of mAbs for in vivo
applications.
The demonstration of the highest pathogenic potency of
the IgG2a isotype highlights the importance of the regula-
tion of IgG isotype responses in both autoantibody-medi-
ated pathology and IC-mediated inflammatory disorders. A
recent study has shown that FcgR-mediated inflammatory
responses play an important role in the pathogenesis of lu-
pus-like glomerulonephritis (44), supporting the possibility
of a higher nephritogenic potential for autoantibodies of
the IgG2a isotype. Although anti-RBC autoantibodies of
the IgG3 isotype are poorly pathogenic, nephritogenic ac-
tivities of IgG3 autoantibodies have also been well estab-
lished, on the basis of a cryoglobulin activity uniquely as-
sociated with the IgG3 heavy-chain C region (45–48).
These findings are consistent with the observation that the
progression of murine lupus-like autoimmune syndrome is
correlated with the relative dominance of Th1 autoim-
mune responses promoting the production of IgG2a and
IgG3 autoantibodies (49–53). Clearly, further studies on
the pathogenic role of autoantibodies according to their Ig
isotypes and in relation with the Th subset responses
would help establish new strategies for the development of
therapeutic approaches in autoantibody-mediated autoim-
mune diseases.
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